Company Overview
About Nephrogen
Nephrogen is a San Francisco-based preclinical gene therapy company — backed by Y Combinator (W20) with $1.1 million in total funding including $775,000 raised to date plus a $325,000 NIH SBIR grant, and currently raising a $4 million seed round with support from StartX and 2048 Ventures — developing curative gene therapies for kidney diseases, with polycystic kidney disease (PKD) as the lead program targeting the 600,000 Americans with the autosomal dominant PKD subtype, an inherited kidney cyst disorder with no disease-modifying treatments that currently progresses to end-stage renal disease requiring dialysis or transplant in the majority of patients. Founded by researchers with combined expertise in AI-driven drug discovery, genetic engineering, and nephrology, Nephrogen applies AI target identification and gene therapy delivery to the largest category of rare inherited kidney diseases.
Business Model & Competitive Advantage
Nephrogen's gene therapy approach to PKD addresses the root cause rather than managing progression: PKD is caused by mutations in the PKD1 or PKD2 genes that disrupt polycystin protein function in kidney tubule cells — causing abnormal fluid-filled cyst growth that progressively replaces normal kidney tissue over decades. Existing therapies (tolvaptan, the only FDA-approved treatment) slow but do not halt PKD progression and carry liver toxicity risks requiring regular monitoring. Nephrogen's gene therapy program uses viral vectors to deliver functional copies of the mutated gene or gene-silencing constructs to kidney cells — targeting the molecular defect rather than downstream cyst growth pathways. The AI drug discovery integration (computational models identifying optimal delivery vectors, expression cassette designs, and dosing regimens from preclinical data) accelerates the iterative optimization that gene therapy development requires. The NIH SBIR grant (Phase I research funding from the National Institute of Diabetes and Digestive and Kidney Diseases) validates the scientific merit of Nephrogen's approach.
Competitive Landscape 2025–2026
In 2025, Nephrogen competes in the gene therapy, rare kidney disease, and genetic medicine market with Passage Bio (rare neurological gene therapy, $216M raised), CRISPR Therapeutics (NASDAQ: CRSP, gene editing, multiple programs), and Oricell Therapeutics (kidney-focused gene therapy) for preclinical PKD gene therapy program development and seed investment in genetic kidney disease. The PKD Foundation estimates 600,000 Americans and 12.5 million people worldwide have ADPKD — making it one of the most common inherited kidney diseases with a large patient population relative to other rare disease targets. Nephrogen's $4 million seed raise target reflects the preclinical stage milestone funding needed to generate the in vivo efficacy and safety data required for IND-enabling studies. The 2025 strategy focuses on demonstrating proof-of-concept gene therapy efficacy in PKD mouse models, building the delivery platform for kidney-targeted gene therapy vectors, and establishing the manufacturing process development foundation.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Nephrogen is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Abridge
Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led b
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
PointClickCare
PointClickCare is North America's leading cloud-based software platform for the long-term and post-acute care (LTPAC) market, headquartered in Mississauga, Ontario, Canada. Founded in 1999, the compan
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Compare Nephrogen with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Nephrogen? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Nephrogen Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Nephrogen vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →